• 1
    Krishnaswamy G, Kelley J, Johnson D, et al. The human mast cell: functions in physiology and disease. Frontiers in Bioscience 2001; 6: D110927.
  • 2
    Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leukaemia Research 2001; 25: 55362.
  • 3
    Peng Q, McEuen AR, Benyon RC, Walls AF. The heterogeneity of mast cell tryptase from human lung and skin. European Journal of Biochemistry 2003; 270: 27083.
  • 4
    Soto D, Malmsten C, Blount JL, Mullenburg DJ, Caughey GH. Genetic deficiency of human mast cell α-tryptase. Clinical and Experimental Allergy 2002; 32: 10006.
  • 5
    Ren S, Sakai K, Schwartz LB. Regulation of human mast cell β-tryptase: Conversion of inactive monomer to active tetramer at acid pH. Journal of Immunology 1998; 160: 45619.
  • 6
    Sakai K, Ren S, Schwartz LB. A novel heparin-dependent processing pathway for human tryptase: autocatalysis followed by activation with dipeptidyl peptidase I. Journal of Clinical Investigation 1996; 97: 98895.
  • 7
    Sakai K, Long SD, Pettit DAD, Cabral GA, Schwartz LB. Expression and purification of recombinant human tryptase in a baculovirus system. Protein Expression and Purification 1996; 7: 6773.
  • 8
    Fajardo I, Pejler G. Formation of active monomers from tetrameric human β-tryptase. Biochemical Journal 2003; 369: 60310.
  • 9
    Alter SC, Kramps JA, Janoff A, Schwartz LB. Interactions of human mast cell tryptase with biological protease inhibitors. Archives of Biochemistry and Biophysics 1990; 276: 2631.
  • 10
    Proud D, Siekierski ES, Bailey GS. Identification of human lung mast cell kininogenase as tryptase and relevance of tryptase kininogenase activity. Biochemical Pharmacology 1988; 37: 147380.
  • 11
    Ren S, Lawson AE, Carr M, Baumgarten CM, Schwartz LB. Human tryptase fibrinogenolysis is optimal at acidic pH, and generates anticoagulant fragments in the presence of antitryptase mAb B12. Journal of Immunology 1997; 159: 35408.
  • 12
    Tam EK, Caughey GH. Degranulation of airway neuropeptides by human lung tryptase. American Journal of Respiratory Cell and Molecular Biology 1990; 3: 2732.
  • 13
    Walls AF, Brain SD, Desai A, et al. Human mast cell tryptase attenuates the vasodilator activity of calcitonin gene-related peptide. Biochemical Pharmacology 1992; 43: 12438.
  • 14
    Lohi J, Harrima I, Keski-Oja J. Pericellular substrates of human mast cell tryptase: 72 000 dalton gelatinase and fibronectin. Journal of Cellular Biochemistry 1992; 50: 33749.
  • 15
    Walls AF, Bennet AR, Sueiras-Diaz J, Olsson H. The kininogenase activity of human mast cell tryptase. Biochemical Society Transactions 1992; 20: 260S.
  • 16
    Cairns JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells: stimulation of IL-8 production and intercellular adhesion molecule-1 expression. Journal of Immunology 1996; 156: 27583.
  • 17
    Brown JK, Tyler CL, Jones CA, Ruoss SJ, Hartman T, Caughey GH. Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells. American Journal of Respiratory Cell and Molecular Biology 1995; 13: 22736.
  • 18
    Ruoss SJ, Hartman T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. Journal of Clinical Investigation 1991; 88: 4939.
  • 19
    Cairns BL, Walls AF. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. Journal of Clinical Investigation 1997; 99: 131321.
  • 20
    Gruber BL, Kew RR, Jelaska A, et al. Human mast cells activate fibroblasts. tryptase is a fibrogenic factor stimulating collagen mRNA and fibroblast chemotaxis. Journal of Immunology 1997; 158: 23107.
  • 21
    Compton SJ, Cairns JA, Holgate ST, Walls AF. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1β and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. Journal of Immunology 1998; 161: 193946.
  • 22
    He S, Gaca MDA, Walls AF. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. Journal of Pharmacology and Experimental Therapeutics 1998; 286: 28997.
  • 23
    Lan RS, Stewart GA, Henry PJ. Role of protease-activated receptors in airway function: a target for therapeutic intervention? Pharmacology and Therapeutics 2002; 95: 23957.
  • 24
    Kawabata A, Kuroda R. Protease-Activated Receptor (PAR), a novel family of G-protein-coupled seven trans-membrane domain receptors: activation mechanisms and physiological roles. Japanese Journal of Pharmacology 2000; 82: 1714.
  • 25
    Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proceedings of the National Academy of Science of the USA 1994; 91: 920812.
  • 26
    Berger P, Tunon-de-Lara JM, Savineau JP, Marthan R. Selected contribution: Tryptase-induced PAR-2-mediated Ca2+ signaling in human airway smooth muscle. Journal of Applied Physiology 2001; 91: 9951003.
  • 27
    Cicala C, Pinto A, Bucci M, et al. Protease-activated receptor-2 involvement in hypotension in normal and endotoxaemic rats in vivo. Circulation 1999; 99: 25907.
  • 28
    Vergnolle N. Proteinase-activated receptors – novel signals for GI pathophysiology. Alimentary Pharmacology and Therapeutics 2000; 14: 25766.
  • 29
    Crowe SE, Perdue MH. Gastrointestinal food hypersensitivity: basic mechanisms of pathophysiology. Gastroenterology 1992; 103: 107595.
  • 30
    Crowe SE, Luthra GK, Perdue MH. Mast cell mediated ion transport in intestine from patients with and without inflammatory bowel disease. Gut 1997; 41: 78592.
  • 31
    Nguyen TD, Moody MW, Steinhoff M, Okolo C, Koh DS, Bunnett NW. Trypsin activates pancreatic duct epithelial cell ion channelS through proteinase-activated receptor-2. Journal of Clinical Investigation 1999; 103: 2619.
  • 32
    Berger A. PAR-2 antagonists – the next generation of anti-inflammatories? British Medical Journal 2000; 320: 334.
  • 33
    Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nature Medicine 2000; 6: 1518.
  • 34
    Huang C, Wong GW, Ghildyal N, et al. The tryptase, mouse mast cell protease 7, exhibits anticoagulant activity in vivo and in vitro due to its ability to degrade fibrinogen in the presence of the diverse array of protease inhibitors in plasma. Journal of Biological Chemistry 1997; 272: 3188593.
  • 35
    Thomas VA, Wheeless CJ, Stack MS. Johnson DA. Human mast cell tryptase fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry 1998; 37: 22918.
  • 36
    Hatanika K, Minamiyama M, Tanaka K, Taguchi T, Tajima S, Kitamura Y. High susceptibility to ADP-induced thrombus formation in mast cell-deficient W/Wv mice. Thrombosis Research 1985; 40: 45364.
  • 37
    Kitamura Y, Taguchi T, Yokoyama M. Higher susceptibility of mast cell-deficient W/Wv mutant mice to brain thromboembolism and mortality caused by intravenous injection of India ink. American Journal of Pathology 1986; 122: 46980.
  • 38
    Dugina TN, Kiseleva EV, Chistov IV, Umarova BA, Strukova SM. Receptors of the PAR family as a link between blood coagulation and inflammation. Biochemistry 2002; 67: 6574.
  • 39
    Samoszuk M, Corwin M, Hazen SL. Effects of human mast cell tryptase on the kinetics of blood clotting. Thrombosis Research 2003; 109: 1536.
  • 40
    Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast cell activation in systemic anaphylaxis and mastocytosis. New England Journal of Medicine 1987; 316: 16226.
  • 41
    Enander I, Matsson P, Nystrand J, et al. A new radioimmunoassay for human mast cell tryptase using monoclonal antibodies. Journal of Immunological Methods 1991; 138: 3946.
  • 42
    Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis. Journal of Clinical Immunology 1994; 14: 190204.
  • 43
    Schwartz LB, Sakai K, Bradford TR, et al. The α form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. Journal of Clinical Investigation 1995; 96: 270210.
  • 44
    Anonymous. UniCAP Tryptase Fluoroenzymeimmunoassay Instruction Manual, Pharmacia and UpJohn, Uppsala, Sweden 2001: 23.
  • 45
    Fisher MM, Baldo BA. Anaphylaxis during anaesthesia. Current aspects of diagnosis and prevention. European Journal of Anaesthesiology 1994; 4: 26384.
  • 46
    Yunginger JW, Nelson DR, Squillace DL, et al. Laboratory investigation of deaths due to anaphylaxis. Journal of Forensic Sciences 1991; 36: 85765.
  • 47
    Enrique E, Garcia-Ortega P, Sotorra O, Gaig P, Richart C. Usefulness of UniCAP Tryptase fluoroimmunoassay in the diagnosis of anaphylaxis. Allergy 1999; 54: 6026.
  • 48
    Forsythe P, Ennis M. Pharmacological regulation of mediator release from human mast cells. Clinical and Experimental Allergy 1998; 28: 11713.
  • 49
    Buckley MG, Variend S, Wall AF. Elevated serum concentrations of β-tryptase, but not α-tryptase, in SIDS. An investigation of anaphylactic mechanisms. Clinical and Experimental Allergy 2001; 31: 1696704.
  • 50
    Holgate ST, Walters C, Walls AF, et al. The anaphylaxis hypothesis of Sudden Infant Death Syndrome: Mast cell degranulation in cot death revealed by elevated concentrations of tryptase in the serum. Clinical and Experimental Allergy 1994; 24: 111522.
  • 51
    Platt MS, Yunginger JW, Sekula-Perlman A, Ivani AA, Schwartz LB. Involvement of mast cells in Sudden Infant Death Syndrome. Journal of Allergy and Clinical Immunology 1994; 94: 2506.
  • 52
    Davies S. Amniotic fluid embolus: a review of the literature. Canadian Journal of Anaesthesia 2001; 48: 8898.
  • 53
    Clark SL, Hankins GDV, Dudley DA, Dildy GA, Porter TF. Amniotic fluid embolism: analysis of the national registry. American Journal of Obstetrics and Gynecology 1995; 172: 115869.
  • 54
    Morgan M. Amniotic fluid embolism: a review. Anaesthesia 1979; 34: 2032.
  • 55
    Fineschi V, Gambassi R, Gherardi M, Turillazzi E. The diagnosis of amniotic fluid embolism: an immunohistochemical study for the quantification of pulmonary mast cell tryptase. International Journal of Legal Medicine 1998; 111: 23843.
  • 56
    Nishio H, Matsui K, Miyazaki T, Tamura A, Iwata M, Suzuki K. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. Forensic Science International 2002; 126: 536.
  • 57
    Benson MD, Kobayashi N, Silver RK, Oi H, Greenberger PA, Terao T. Immunologic studies in presumed amniotic fluid embolism. Obstetrics and Gynecology 2001; 97: 5104.
  • 58
    Austen FK. Allergies, anaphylaxis and systemic mastocytosis. In: BraunwaldE, FauceAS, KasperDL, HauserSL, LangoDL, JamesonJL, eds. Harrison's Principles of International Medicine, 15th edn. New York: McGraw-Hill, 2001: 191920.
  • 59
    Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 46606.
  • 60
    Sperr WR, Stehberger B, Wimazal F, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leukemia and Lymphoma 2002; 43: 1097105.
  • 61
    Mertes PM, Laxenaire M-C. Allergic reactions occurring during anaesthesia. European Journal of Anaesthesiology 2002; 19: 24062.
  • 62
    Fisher MM, Baldo BA. The incidence and clinical features of anaphylactic reactions during anaesthesia in Australia. Annales Francaises d'Anesthesie et de Reanimation 1993; 12: 97104.
  • 63
    Currie M, Webb RK, Williamson JA, Russell WJ, Mackay P. The Australian Incident Monitoring Study. Clinical anaphylaxis: an analysis of 2000 incident reports. Anaesthesia and Intensive Care 1993; 21: 6215.
  • 64
    Porri F, Lemiere C, Birnbaum J, et al. Prevalence of muscle relaxant sensitivity in a general population: implications for a preoperative screening. Clinical and Experimental Allergy 1999; 29: 725.
  • 65
    Laxenaire MC. Epidemiologie des reactions anaphylactoids peranesthesiques. Quatrieme enquete multicentrique (juillet 1994-decembre 1996). Annales Francaises d'Anesthesie et de Reanimation 1999; 18: 796809.
  • 66
    Fisher MM, Baldo BA. Mast cell tryptase in anaesthetic anaphylactoid reactions. British Journal of Anaesthesia 1998; 80: 269.
  • 67
    Laxenaire MC. Drugs and other agents involved in anaphylactic shock occurring during anaesthesia. A French multicentre epidemiological inquiry. Annales Francaises d'Anesthesie et de Reanimation 1993; 12: 916.
  • 68
    Laxenaire MC. Substances responsible for preanesthetic anaphylactic shock. A third French multicentre study (1992–94). Annales Francaises d'Anesthesie et de Reanimation 1996; 15: 12118.
  • 69
    Mertes PM, Laxenaire M-C, Alla F. Anaphylactic and anaphylactoid reactions occuring during anesthesia in France 1999–2000. Anesthesiology 2003; 99: 53645.
  • 70
    Laroche D, Vergnaud MC, Sillard B, Soufarapis H, Bricard H. Biochemical markers of anaphylactoid reactions to drugs. Comparison of plasma histamine and tryptase. Anesthesiology 1991; 75: 9459.
  • 71
    Dybendal T, Guttormsen AB, Elsayed S, Askeland B, Harboe T, Florvaag E. Screening for mast cell tryptase and serum IgE antibodies in 18 patients with anaphylactic shock during general anaesthesia. Acta Anaesthesiologica Scandinavica 2003; 47: 12118.